NUCIEN PHARMA terminates the planning of major asset restructuring matters
NUCIEN PHARMA announced the termination of the significant asset restructuring with Future Pharma. The company had planned to acquire the target asset group of Future Pharma in cash, but after multiple discussions and negotiations, they failed to reach an agreement on the core terms of the transaction. To protect the interests of the company and its shareholders, the parties involved decided to terminate the transaction and signed the "Acquisition Termination Agreement."
According to the Zhitong Finance APP, NUCIEN PHARMA (688189.SH) announced that it had previously signed a "Acquisition Intent Agreement" with Tibet Future Biopharmaceutical Co., Ltd., Xuchang Future Pharmaceutical Co., Ltd., and Hefei Future Drug Development Co., Ltd. (hereinafter collectively referred to as "Future Pharmaceuticals" or "Target Company") to acquire the target asset group held by Future Pharmaceuticals in cash.
After signing the "Acquisition Intent Agreement," the company actively organized all parties involved in the transaction to advance the deal. The company and the counterparty conducted multiple evaluations and discussions regarding the feasibility of the transaction and the core terms of the transaction plan, but ultimately failed to reach a consensus on the core terms of the transaction. In order to effectively safeguard the interests of the company and all shareholders, after careful research and friendly negotiations with the counterparty, all parties involved in the transaction unanimously agreed to terminate the planning of this transaction and recently signed the "Acquisition Termination Agreement."
